Patient Interstitial: Receiving a Novel mRNA Cancer Vaccine [STAT Summit 2026 Review #24]

Report 24. Patient Interstitial: Receiving a Novel mRNA Cancer Vaccine

Part I. English Version

1. Event / Date & Time

Event: Patient Interstitial: Receiving a Novel mRNA Cancer Vaccine (Virtual Session)

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 11:10 AM EDT

2. Participants

Speakers

- Gary Keblish — Clinical Trial Participant; Patient with High-Risk Melanoma

3. Summary

Personalized Cancer Vaccine Experience: A patient with high-risk melanoma described participating in a trial combining an investigational mRNA cancer vaccine with immunotherapy.

Clinical Trial Participation: The account illustrated the uncertainty, hope and treatment-related symptoms encountered during early access to innovative therapy.

Patient Perspective: The testimony emphasized the value of clear clinician communication and individual support throughout experimental treatment.

4. Main Discussion

Diagnosis and Trial Enrollment

Gary Keblish, a public school teacher, described receiving a high-risk melanoma diagnosis in 2019 and undergoing surgical evaluations. After meeting clinician Jeffrey Weber at NYU Langone’s Perlmutter Cancer Center, he entered a study combining Merck’s pembrolizumab (Keytruda) with a personalized mRNA cancer vaccine developed through the Moderna–Merck partnership.

Keblish described a sequence of dermatology evaluation, excisions and referral to surgical and medical oncology after his 2019 high-risk melanoma diagnosis. His testimony conveyed uncertainty at each step, including whether more surgery would be sufficient and whether trial participation was the right choice. He ultimately enrolled at NYU Langone under the care of Jeffrey Weber in a study combining an mRNA-based individualized vaccine with the PD-1 immunotherapy pembrolizumab. The session did not present his mutation profile, clinical stage details, imaging measurements or formal response endpoints. For that reason, the report treats his experience as qualitative testimony about care and trial participation rather than proof of vaccine effectiveness.

Gary Keblish’s video testimony situated a personalized cancer vaccine within a clinical history rather than describing it as an independent cure. He recounted a high-risk melanoma diagnosis in 2019, surgical excisions and referrals to oncology specialists before he was offered trial participation. His selection involved eligibility and random assignment, which he experienced as a moment of both uncertainty and hope. The treatment combined pembrolizumab (Keytruda) with an investigational mRNA vaccine developed through the Moderna–Merck collaboration. The session provided one participant’s experience and did not supply a study-wide effect size, randomized comparison or evidence that his outcome was caused by the vaccine alone.

Treatment Experience and Monitoring

Keblish compared participation in the trial to an unpredictable journey involving emotional adjustments and physical changes, including neuropathy-related difficulties. He described the importance of supportive medical teams while managing side effects and uncertainty. His remarks represented a personal account, not evidence that the regimen is effective for all melanoma patients.

The patient used the metaphor of an unpredictable journey to describe participation in a trial. He spoke of physical and emotional fluctuations, including neuropathy-related problems, and described how uncertainty gradually changed as his treatment and recovery progressed. This framing matters because individualized cancer therapies involve more than receipt of a medicine: patients encounter information about eligibility, clinicians’ recommendations, possible adverse effects and repeated monitoring. The account also credited clinical staff for guidance and reassurance, rather than presenting the patient as navigating unfamiliar technology alone. The testimony did not compare the frequency of his symptoms with other trial participants or establish that such symptoms were caused by the investigational vaccine.

The patient described treatment as an unpredictable journey involving changing physical symptoms and emotions. Peripheral neuropathy and other challenges influenced his daily activities and confidence, while support from clinicians and his personal network helped him continue. He used the children’s program The Magic School Bus as a metaphor for embarking on a difficult scientific adventure whose destination could not be known in advance. The metaphor illustrated a practical aspect of consent: patients enter novel trials while having to understand evolving risks, schedules and possible benefits. Patient navigation, ongoing explanation and follow-up should therefore be considered components of translational research rather than ancillary hospitality.

Patient Voice in Novel Oncology Research

The short prerecorded patient segment preceded a discussion with executives from Moderna and Merck. It brought the practical and emotional dimensions of personalized treatment into a drug-development conversation otherwise focused on clinical programs and scientific advances.

The video was placed immediately before an executive discussion of the Moderna–Merck cancer vaccine program, giving the subsequent scientific and manufacturing conversation a patient perspective. A person’s willingness to enroll in an investigational study can depend on the clarity of information and the degree of trust in the treatment team, particularly when the therapy is novel. Keblish’s narrative demonstrated how a patient experiences decision-making over time rather than a single consent event. The central evidence is the firsthand account itself; it should be read alongside controlled trial findings and safety data when evaluating the development program. Patients’ experiences may guide better communication without substituting for comparative clinical evidence.

The testimony preceded a longer interview with executives from both partner companies. Its position in the program was significant: a participant spoke before corporate leaders explained scientific results and business strategy. That ordering kept attention on the person affected by a complex platform, not only the novelty of mRNA technology. His account nevertheless cannot answer questions about comparative efficacy, optimal patient selection, long-term toxicity or manufacturing scale. Such issues require carefully designed clinical studies and reproducible data. The report therefore treats the video as qualitative evidence of a patient journey, complementary to but separate from the clinical evidence discussed in the following session.

Keblish identified the clinical team around Jeffrey Weber at NYU Langone as central to his treatment experience. He described ongoing visits and conversations as helping him remain focused while coping with neuropathy and reduced physical activity. The challenges were not limited to measurable adverse events: he said physical symptoms affected his outlook and sense of agency, and his family helped him recognize those changes. The testimony therefore points to the value of continuity, mental and physical symptom monitoring, and clear explanation during a demanding investigational regimen. These themes can inform patient-experience research even though the video does not provide validated patient-reported outcome scores.

As a public-school teacher, Keblish framed recovery through the ability to continue teaching and return to the classroom. He said six years had passed since his tumor was removed and expressed gratitude for being able to resume ordinary responsibilities. That account is an important patient-defined outcome, but it is not a statement that the disease is cured or that all trial participants will experience similar trajectories. The preceding surgery, trial assignment, accompanying pembrolizumab and ongoing clinical care make attribution to a single component impossible from the testimony alone. The patient story should be read as a reminder to include meaningful everyday functioning in clinical development.

His account also illustrated the role of clinical-trial participation during the COVID-19 pandemic, when routine interactions with medical services were themselves under strain. Keblish spoke appreciatively of physicians, nurses and supporting staff who maintained contact and helped him work through uncertainty. That gratitude is a personal assessment, not a measure of treatment effectiveness. Nevertheless, it identifies clinical infrastructure and the reliability of the care team as factors that may determine whether patients can adhere to demanding protocols. In individualized oncology research, safe delivery is as dependent on communication and follow-through as it is on manufacturing a scientifically sophisticated product.

5. Insights

Patient-Reported Evidence: Early oncology studies can gain context by systematically incorporating adverse effects and lived treatment experiences.

Implications for South Korea: Korean clinical research programs could create more structured opportunities for patients to share experiences during experimental therapy.

Patient–Researcher Dialogue: Direct patient participation may help align innovative oncology development with informed consent and supportive care needs.

Report 24. Patient Interstitial- Receiving a Novel mRNA Cancer Vaccine (Virtual Session)_e

Download PATIENT INTERSTITIAL- RECEIVING A NOVEL MRNA CANCER VACCINE (VIRTUAL SESSION)_E • 71KB